Plain-English translation of NCT06699420 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a traditional Chinese medicine called Qishenyiqi Dripping Pill in patients with coronary microvascular disease — a condition where the tiny blood vessels in your heart don't deliver enough blood, causing chest pain even though your larger coronary arteries are normal. Researchers want to see if this medication can reduce chest pain episodes and improve how well blood flows through your heart over one year of treatment.
Many people experience chest pain from small blood vessel problems in the heart, but standard treatments don't always work well for them. This trial is investigating whether this medication could offer relief for patients whose condition is difficult to manage with current options.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the Qishenyiqi Dripping Pill or a placebo (inactive pill) for one year. During this time, you'll have regular visits to take the medication, report on your chest pain symptoms, and undergo heart tests to measure how well the small blood vessels in your heart are working. The study includes a one-year follow-up period to see if the medication reduces chest pain episodes and improves your heart's blood flow.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
China